This technology involves compositions for increasing milk yield and feed additives containing Ephrin A1 as an active ingredient, as well as pharmaceutical and food compositions for the prevention and treatment of mastitis. It also includes a method for enhancing the proliferative capacity of mammary epithelial cells derived from non-human mammals.
Mammary epithelial cells form the mammary glands and are directly responsible for milk production, making the maintenance of their proliferative capacity essential for milk yield. Persistent inflammation leading to mastitis reduces casein and calcium levels in milk, compromising quality. While it was previously reported that Ephrin B2 is associated with the malignancy of mammary cells, the role of Ephrin A1 in mammary epithelial cell proliferation and inflammatory responses remained unknown.
This technology utilizes the ability of Ephrin A1 to activate PI3K/AKT and MAPK signaling pathways to enhance mammary epithelial cell proliferation, while reducing the expression of endoplasmic reticulum stress-induced proteins such as IRE1α, ATF6α, PERK, GRP78, and GADD153 to alleviate inflammatory responses. As it uses a protein synthesized within the body, it carries fewer risks of toxicity and side effects compared to chemical synthetics. It can be applied to milk-boosting feed additives for dairy cows, mastitis prevention and treatment for dairy farms, and lactation-related functional foods, thereby increasing milk production per cow while reducing raw milk quality degradation and economic losses caused by mastitis.
This invention was developed with support from the Ministry of Health and Welfare for verifying the efficacy of fetal-derived mesenchymal stem cell therapies for treating inflammatory preterm birth.
N/A
